These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 1318674)
21. In vitro activity of HSR-903, a new quinolone. Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193 [TBL] [Abstract][Full Text] [Related]
22. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237 [TBL] [Abstract][Full Text] [Related]
23. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. Louie A; Baltch AL; Ritz WJ; Smith RP J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857 [TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740 [TBL] [Abstract][Full Text] [Related]
25. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895 [TBL] [Abstract][Full Text] [Related]
26. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci]. Wallrauch C; Voss A; Milatovic D; Braveny I Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580 [TBL] [Abstract][Full Text] [Related]
27. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Fuchs PC; Barry AL; Pfaller MA; Allen SD; Gerlach EH Antimicrob Agents Chemother; 1991 Apr; 35(4):764-6. PubMed ID: 2069384 [TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of four new fluoroquinolones. García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215 [TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Masuda N; Takahashi Y; Otsuki M; Ibuki E; Miyoshi H; Nishino T Antimicrob Agents Chemother; 1996 May; 40(5):1201-7. PubMed ID: 8723467 [TBL] [Abstract][Full Text] [Related]
31. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Forstall GJ; Knapp CC; Washington JA Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873 [TBL] [Abstract][Full Text] [Related]
32. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Aldridge KE Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307 [TBL] [Abstract][Full Text] [Related]
33. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone. Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824 [TBL] [Abstract][Full Text] [Related]
34. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651 [TBL] [Abstract][Full Text] [Related]
35. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Nukiwa T Antimicrob Agents Chemother; 1999 Jul; 43(7):1767-8. PubMed ID: 10390240 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Dalhoff A; Petersen U; Endermann R Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575 [TBL] [Abstract][Full Text] [Related]
38. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. Cormican MG; Jones RN J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474 [TBL] [Abstract][Full Text] [Related]
39. Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. Rohner P; Peebo M; Lew DP; Auckenthaler R; Pechère JC J Antimicrob Chemother; 1992 Jan; 29(1):41-8. PubMed ID: 1737723 [TBL] [Abstract][Full Text] [Related]
40. In vitro antibacterial activity of Q-35, a new fluoroquinolone. Ito T; Otsuki M; Nishino T Antimicrob Agents Chemother; 1992 Aug; 36(8):1708-14. PubMed ID: 1329626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]